Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01788657
Other study ID # Dnr 63:2012
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 29, 2013
Est. completion date December 3, 2017

Study information

Verified date March 2023
Source Örebro County Council
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Internet-based cognitive behavior therapy (iCBT) has been shown effective for depression in several studies, however the investigators know very little about how the written treatment material should be designed to be effective and at the same time acceptable to the patients. The investigators are not aware of any research that has investigated if slow readers, or persons with difficulty concentrating, can use the standard material or if they would benefit more from using an adapted version. In this study the investigators will assess reading speed and the ability to concentrate in all patients and then randomise them to an internet-based treatment for depression using either a standard material or a condensed one. The condensed material consists of 30000 words and will be available as text files and on audio files. The standard material consists of 60000 words and is only available as text files. Both groups will have the possibility of e-mail contact with a personal therapist during the treatment. Patients will be recruited within Örebro County by referrals and self-referrals. The goal is to recruit between 200 and 300 patients during 2 years. The treatment time will be 10 weeks and all patients will be assessed for depression at an interview with a psychologist. There will also be interviews after treatment and one year after treatment. The most important outcome will be depressive symptoms.


Recruitment information / eligibility

Status Completed
Enrollment 273
Est. completion date December 3, 2017
Est. primary completion date December 3, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Fullfill criteria for diagnosis of major depression - Being able to read and write Swedish - Have access to the internet - Being a resident in Örebro county Exclusion Criteria: - Severe depressive symptoms (>34 on the MADRS-S) - High risk for suicide - Attending cognitive behavior therapy - Psychosis - Bipolar disorder - Addiction to alcohol or illegal drugs - A somatic or psychiatric condition that is a contraindication for iCBT or in some way debars iCBT, or have to be treated before depression

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Standard internet-based cognitive behavior therapy
Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
Condensed internet-based cognitive behavior therapy
Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention

Locations

Country Name City State
Sweden Örebro County Council Örebro Örebro County

Sponsors (2)

Lead Sponsor Collaborator
Örebro County Council Karolinska Institutet

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Reading speed To assess reading speed the "Diagnostiskt Läs och Skrivprov" (DLS) will be administered during the pre treatment interview. Pre treatment
Other Ability to concentrate To assess the ability to concentrate six items from the WHO adult scale for attention deficit disorder (ASRS-VI.I) will be administered during the pre treatment interview. Pre treatment
Other Change from baseline in risk for suicide Change in risk for suicide will be measured by item 9 in the MADRS-S every week After 1,2,3,4,5,6,7,8,9,10,11,12 weeks
Primary Change from baseline in depressive symptoms at post-treatment and after 12 months Depressive symptoms will be measured by the self-report measure Montgomery-Åsberg Depression Rating Scale- self-rated. At baseline, after 12 weeks, after 12 months
Secondary Change from baseline in diagnostic status for Major depression The diagnostic status (depression) will be assessed in a face-to-face interview using the structured material Mini-International Neuropsychiatric Interview (M.I.N.I.). Pre-treatment, after 12 weeks and after 1 year
Secondary Change from baseline in symptoms of anxiety Symptoms of anxiety will be conducted using the self-report measure Beck Anxiety Inventory (BAI) Pre-treatment, after 12 weeks and after 1 year
Secondary Post-treatment treatment satisfaction Post-treatment treatment satisfaction will be measured by the self-report measure Client Satisfaction Questionnaire (CSQ) After 12 weeks
Secondary Therapist time Therapist time will be measured automatically by the IT-platform and assesses the time spent on each patient by each therapist. A mean time will be calculated to report an estimated time needed to treat one patient with the two interventions. Post treatment
Secondary Alcohol use To assess alkolhol use the AUDIT-questionnaire will be filled out at pre treatment. Pre treatment
Secondary Drug use To assess drug use the DUDIT-questionnaire will be filled out at pre treatment. Pre treatment
Secondary Treatment satisfaction at follow up Treatment satisfaction at follow up will be measured by the self-report measure Client Satisfaction Questionnaire (CSQ) After 1 year
See also
  Status Clinical Trial Phase
Completed NCT03062150 - Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression N/A
Completed NCT04352101 - Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits Phase 4
Completed NCT02855918 - Blood Biomarkers in Suicidal Behaviour N/A
Recruiting NCT03039387 - Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients N/A
Recruiting NCT02213016 - Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Phase 4
Completed NCT01636791 - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care Phase 3
Completed NCT01683539 - Understanding How Cognitive Remediation Works N/A
Recruiting NCT02237937 - Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Phase 4
Completed NCT01201148 - Open Pilot Trial of TES for Depression Phase 2
Completed NCT00953108 - Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients Phase 3
Terminated NCT01244711 - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines Phase 4
Completed NCT00806143 - Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression Phase 4
Terminated NCT00695552 - The Effect of Exercise on Depressive Symptoms in Unmedicated Patients N/A
Completed NCT00711737 - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months N/A
Completed NCT00532480 - Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine Phase 4
Completed NCT00482482 - Yoga in Unipolar and Bipolar Disorders N/A
Completed NCT00466323 - The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness. N/A
Completed NCT00616759 - The Effect on Cognition of Terminating ECT Induced Seizures With Propofol N/A
Recruiting NCT00209807 - Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Phase 4
Completed NCT00167310 - Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation Phase 2